Emerging roles of RNA and RNA-binding protein network in cancer cells

  • Kim, Mee-Young ;
  • Hur, Jung ;
  • Jeong, Sun-Joo
  • Published : 2009.03.31


Recent advances in RNA biology reveal unexpected diversity and complexity of cellular RNA metabolism. RNA-binding proteins (RBPs) are essential players in RNA metabolism, regulating RNA splicing, transport, surveillance, decay and translation. Aberrant expression of RBPs affects many steps of RNA metabolism, significantly altering expression of RNA. Thus, altered expression and dysfuncting of RBPs are implicated in the development of various diseases including cancer. In this minireview, we briefly describe emerging roles of RBPs as a global coordinator of post-transcriptional steps and altered RBP as a global generator of cancer related RNA alternative splicing. Identification and characterization of the RNA-RBP network would expand the scope of cellular RNA metabolism and provide novel anti-cancer therapeutic targets based on cancer specific RNA-RBP interaction.


Alternative splicing;Cancer;RNA-binding protein (RBP);RNA metabolism


  1. Keene, J. D. (2007) RNA regulons: coordination of post-transcriptional events. Nat. Rev. Genet. 8, 533-543
  2. Birzele, F., Csaba, G. and Zimmer, R. (2008) Alternative splicing and protein structure evolution. Nucleic. Acids. Res. 36, 550-558
  3. House, A. E. and Lynch, K. W. (2008) Regulation of alternative splicing: more than just the ABCs. J. Biol. Chem. 283, 1217-1221
  4. Stamm, S. (2008) Regulation of alternative splicing by reversible protein phosphorylation. J. Biol. Chem. 283, 1223-1227
  5. Wang, G. S. and Cooper, T. A. (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 8, 749-761
  6. and Montuenga, L. M. (2007) Alternative splicing: an emerging topic in molecular and clinical oncology. Lacent. Onc. 8, 349-357
  7. Audic, Y. and Hartley, R. S. (2004) Post-transcriptional regulation in cancer. Biol. Cell 96, 479-498
  8. Naor, D., Nedvetzki, S., Golan, I., Melnik, L. and Faitelson, Y. (2002) CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 39, 527-579
  9. Karni, R., Hippo, Y. Lowe, S. W. and Krainer, A. R. (2008) The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc. Natl. Acad. Sci. U. S. A. 105, 15323-15327
  10. Lukong, K. E. and Richard, S. (2003) Sam68, the KH domain- containing superSTAR. Biochim. Biophys. Acta. 1653, 73-86
  11. Lee, H. K., Kwak, H. Y., Hur, J., Kim, I. A., Yang, J. S., Park, M. W., Yu, J. and Jeong, S. (2007) $\beta$-catenin regulates multiple steps of RNA metabolism as revealed by RNA aptamer in colon cancer cells. Cancer Res. 67, 9315-9321
  12. Licatalosi, D. D., Mele, A., Fak, J. J., Kayikci, M., Chi, S. W., Clark, T. A., Schweitzer, A. C., Blume, J. E., Wang, X., Darnell, J. C. and Darnell, R. B. (2008) HITS-CLIP yields genome- wide insights into brain alternative RNA processing. Nature 456, 464-469
  13. Lee, H. K. and Jeong, S. (2006) $\beta$-catenin stabilizes cyclooxygenase- 2 mRNA by interacting with AU-rich elements of 3'-UTR. Nucleic. Acids. Res. 34, 5705-5714
  14. Li, H., Watford, W., Li, C., Parmelee, A., Bryant, M. A., Deng, C., O'Shea, J. and Lee, S. B. (2007) Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J. Clin. Incest. 117, 1314-1323
  15. Fedor, M. J. (2008) Alternative splicing minireview series: combinatorial control facilitates splicing regulation of gene expression and enhances genome diversity. J. Biol. Chem. 283, 1209-1210
  16. Kim, E., Goren, A. and Ast, G. (2008) Insights into the connection between cancer and alternative splicing. Trends Genet. 24, 7-10
  17. Riggi, N., Cironi, L., Suv$\grave{a}$, M. L. and Stamenkovic, I. (2007) Sarcomas:genetics, signaling, and cellular origins. Part 1: The fellowship of TET. J. Pathol. 213, 4-20
  18. Glisovic, T., Bachorik, J. L., Yong, J. and Dreyfuss, G. (2008) RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 582, 977-1986
  19. Lukong, K. E., Chang K. W., Khandjian, E. W. and Richard, S. (2008) RNA-binding proteins in human genetic disease. Trends Genet. 24, 416-425
  20. Kim, E. Goren, A. and Ast, G. Alternative splicing and disease. RNA Biol. 5, 1-3
  21. and Ilaria, R. L. Jr. (2005) Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res. 65, 8698-8705
  22. Maniatis, T. and Reed, R. (2002) An extensive network of coupling among gene expression machines. Nature 416, 499-506
  23. Stickeler, E., Kittrell, F., Medina, D. and Berget, S. M. (1999) Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18, 3574-3582
  24. Orend, G. and Chiquet-Ehrismann, R. (2006) Tenascin-C induced signaling in cancer. Cancer Lett. 8, 143-163
  25. Ferrara, N., Gerber, H. P. and LeCouter, J. (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676
  26. Cooper, T. A., Wan, L. and Dreyfuss, D. (2009) RNA and disease. Cell 136, 777-793
  27. Bus$\grave{a}$, R., Paronetto, M. P., Farini, D., Pierantozzi, E., Botti, F., Angelini, D. F. and Attisani, F. (2007) The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 26, 4372-4382
  28. and Krainer, A. R. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14, 185-193
  29. Sharp, P. A. (2009) The centrality of RNA. Cell 136, 577- 580
  30. Moore, M. J. and Proudfoot, N. J. (2009) Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 136, 688-700
  31. Huang, Y. and Steitz, J. A. (2005) SRprises along a messenger's journey. Mol. Cell 17, 613-615
  32. Stamm, S., Ben-Ari, S., Rafalska, I., Tang, Y., Zhang, Z., Toiber, D., Thanaraj, T. A. and Soreq, H. (2005) Function of alternative splicing. Gene 344, 1-20
  33. Yin, Y., Chung, P., de Rooij, D. G., Akhmedov, A., Ashley, T. and Ron, D. (2000) Male sterility and enhanced radiation sensitivity in TLS (-/-) mice. EMBO J. 19, 453-462
  34. Lee, H. K., Choi, Y. S., Park, Y. A. and Jeong, S. (2006) Modulation of oncogenic transcription and alternative splicing by $\beta$-catenin and an RNA aptamer in colon cancer cells. Cancer Res. 66, 10560-10566
  35. Orphanides, G. and Reinberg, D. (2002) A unified theory of gene expression. Cell 108, 439-451
  36. Sanford, J. R., Coutinho, P., Hackett, J. A., Wang, X., Ranahan, W. and Caceres, J. F. (2008) Identification of nuclear and cytoplasmic mRNA targets for the shuttling protein SF2/ASF. PLoS ONE 3, e3369
  37. Matter, N., Herrlich, P. and K$\ddot{o}$nig, H. (2002) Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420, 691-695
  38. Grunstein, J., Masbad, J. J., Hickey, R., Giordano, F. and Johnson, R. S. (2000) Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol. Cell Biol. 20, 7282-7291
  39. Michlewski, G., Sanford, J. R. and Caceres, J. F. (2008) The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol. Cell 30, 179-189
  40. Lunde, B. M., Moore, C. and Varani, G. (2007) RNA-binding proteins: modular design for efficient function. Nat. Rev. Mol. Cell Biol. 8, 479-490
  41. Scholzov$\acute{a}$, E., Mal$\acute{i}$k, R., $\check{S}$ev$\check{c}$ik, J. and Kleibl, Z. (2007) RNA regulation and cancer development. Cancer Lett. 246, 12-23
  42. Jele, N. Ule, J., Zivin, M. and Darnell, R. B. (2007) Evolution of Nova-dependent splicing regulation in the brain. PLoS Genet. 3, e173
  43. Hertel, K. J. (2008) Combinatorial control of exon recognition. J. Biol. Chem. 283, 1211-1215
  44. Xu, Q. and Lee, C. (2003) Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic. Acids. Res. 31, 5635-5643
  45. Cech, T. R. (2009) Crawling out of RNA world. Cell 136, 599-602
  46. Sanford, J. R., Gray, N. K., Beckmann, K. and Caceres, J. F. (2004) A novel role for shuttling SR proteins in mRNA translation. Genes. Dev. 18, 755-768
  47. Ben-Dov, C., Hartmann, B., Lundgren, J. and Valcarcel, J. (2008) Genome-wide analysis of alternative pre-mRNA splicing. J. Biol. Chem. 283, 1229-1233
  48. Sonenberg, N. and Hinnebusch, A. G. (2007) New modes of translational control in development, behavior, and disease. Mol. Cell 28, 721-729
  49. Hogan, D. J., Riordan, D. P., Gerber, A. P., Herschlag, D. and Brown, P. O. (2008) Diverse RNA-binding proteins interact with functionally related sets of RNAs, suggesting an extensive regulatory system. PLoS Biol. 6, e255
  50. Sanford, J. R., Ellis, J. D., Cazalla, D. and Caceres, J. F. (2005) Reversible phosphorylation differentially affects nuclear and cytoplasmic functions of splicing factor 2/alter native splicing factor. Proc. Natl. Acad. Sci. U. S. A. 102, 15042-15047
  51. Gerber, A. P., Herschlag, D. and Brown, P. O. (2004) Extensive association of functionally and cytotopically related mRNAs with Puf family RNA-binding protein in yeast. PLoS Biol. 2, 342-354
  52. Torchia, E. C., Boyd, K., Rehg, J. E., Qu, C. and Baker, S. J. (2007) EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol. Cell Biol. 27, 7918-7934
  53. Fleischer, T. C., Weaver, C. M., McAfee, K. J., Jennings, J. L. and Link, A. J. (2006) Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexes. Genes Dev. 20, 1294-1307
  54. Venables, J. P. (2004) Aberrant and alternative splicing in cancer. Cancer Res. 64, 7647-7654

Cited by

  1. RPI-Pred: predicting ncRNA-protein interaction using sequence and structural information vol.43, pp.3, 2015,
  2. Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer vol.28, pp.S1, 2011,
  3. Dysregulated transcription across diverse cancer types reveals the importance of RNA-binding protein in carcinogenesis vol.16, pp.Suppl 7, 2015,
  4. Comparability of differential proteomics data generated from paired archival fresh-frozen and formalin-fixed samples by GeLC–MS/MS and spectral counting vol.77, 2012,
  5. Splicing Programs and Cancer vol.2012, 2012,
  6. Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer vol.34, pp.4, 2013,
  7. Versatility of RNA-Binding Proteins in Cancer vol.2012, 2012,
  8. HuR and post-transcriptional regulation in vascular aging vol.57, pp.8, 2014,
  9. ZFP36L1 promotes monocyte/macrophage differentiation by repressing CDK6 vol.5, pp.1, 2015,
  10. p53 is activated in response to disruption of the pre-mRNA splicing machinery vol.32, pp.1, 2013,
  11. Dissecting the expression dynamics of RNA-binding proteins in posttranscriptional regulatory networks vol.106, pp.48, 2009,
  12. Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors vol.111, pp.52, 2014,
  13. The DEAD-box RNA helicase DDX41 is a novel repressor of p21WAF1/CIP1mRNA translation vol.292, pp.20, 2017,
  14. High Expression of HuR in Cytoplasm, but Not Nuclei, Is Associated with Malignant Aggressiveness and Prognosis in Bladder Cancer vol.8, pp.3, 2013,
  15. β-Catenin recognizes a specific RNA motif in the cyclooxygenase-2 mRNA 3′-UTR and interacts with HuR in colon cancer cells vol.40, pp.14, 2012,
  16. Computationally predicting protein-RNA interactions using only positive and unlabeled examples vol.13, pp.03, 2015,
  17. Given Dimensions of Neoplastic Events as Aberrantly Operative Alternative Splicing vol.2010, 2010,
  18. Wig1 prevents cellular senescence by regulating p21 mRNA decay through control of RISC recruitment vol.31, pp.22, 2012,
  19. Using RNA as Molecular Code for Programming Cellular Function vol.5, pp.8, 2016,
  20. Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction vol.36, pp.2, 2015,
  21. A quantitative RNA code for mRNA target selection by the germline fate determinant GLD-1 vol.30, pp.3, 2011,
  22. MKP-1 regulates cytokine mRNA stability through selectively modulation subcellular translocation of AUF1 vol.56, pp.2, 2011,
  23. Posttranscriptional regulation of cancer traits by HuR vol.1, pp.2, 2010,
  24. Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma vol.35, pp.1, 2014,
  25. Certain Adenylated Non-Coding RNAs, Including 5′ Leader Sequences of Primary MicroRNA Transcripts, Accumulate in Mouse Cells following Depletion of the RNA Helicase MTR4 vol.9, pp.6, 2014,
  26. Cold-inducible RNA binding protein in mouse mammary gland development vol.48, pp.6, 2016,
  27. 3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes vol.284, pp.17, 2017,
  28. Dissecting the expression landscape of RNA-binding proteins in human cancers vol.15, pp.1, 2014,
  29. Guardian of Genetic Messenger-RNA-Binding Proteins vol.6, pp.1, 2016,
  30. Inferring RBP-Mediated Regulation in Lung Squamous Cell Carcinoma vol.11, pp.5, 2016,
  31. Interplay between Posttranscriptional and Posttranslational Interactions of RNA-Binding Proteins vol.409, pp.3, 2011,
  32. Seten: a tool for systematic identification and comparison of processes, phenotypes, and diseases associated with RNA-binding proteins from condition-specific CLIP-seq profiles vol.23, pp.6, 2017,
  33. Predicting RNA-Protein Interactions Using Only Sequence Information vol.12, pp.1, 2011,
  34. RNA regulatory networks in animals and plants: a long noncoding RNA perspective vol.14, pp.2, 2015,
  35. The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation vol.41, 2016,
  36. The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation, migration, and invasion vol.39, pp.5, 2017,
  37. Mitochondrial ribosomes in cancer 2017,
  38. RNA Binding Proteins in the miRNA Pathway vol.17, pp.1, 2015,
  39. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis vol.59, pp.4, 2013,
  40. Aberrant Regulation and Function of MicroRNAs in Cancer vol.24, pp.16, 2014,
  41. Prediction of lncRNA-protein interactions using HeteSim scores based on heterogeneous networks vol.7, pp.1, 2017,
  42. HuR cytoplasmic expression is associated with increased cyclin A expression and inferior disease-free survival in patients with gastrointestinal stromal tumours (GISTs) 2013,
  43. Expression of the ELAV-like protein HuR in the cytoplasm is associated with endometrial carcinoma progression vol.35, pp.12, 2014,
  44. Dynamics in multi-domain protein recognition of RNA vol.22, pp.3, 2012,
  45. RNA-binding proteins, multifaceted translational regulators in cancer vol.1849, pp.7, 2015,
  46. From specific to global analysis of posttranscriptional regulation in eukaryotes: posttranscriptional regulatory networks vol.11, pp.6, 2012,
  47. Knockdown of hMex-3A by small RNA interference suppresses cell proliferation and migration in human gastric cancer cells vol.6, pp.3, 2012,
  48. Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity vol.2, 2011,
  49. Regulatory RNA-binding proteins in senescence vol.11, pp.4, 2012,
  50. RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer vol.14, pp.1, 2014,
  51. Targeted mRNA Decay by RNA Binding Protein AUF1 Regulates Adult Muscle Stem Cell Fate, Promoting Skeletal Muscle Integrity vol.16, pp.5, 2016,
  52. Co- and post-transcriptional regulation of Rbm5 and Rbm10 in mouse cells as evidenced by tissue-specific, developmental and disease-associated variation of splice variant and protein expression levels vol.580, pp.1, 2016,
  53. Compounds Interfering with Embryonic Lethal Abnormal Vision (ELAV) Protein–RNA Complexes: An Avenue for Discovering New Drugs 2017,
  54. microRNAs and RNA-binding proteins vol.10, pp.6, 2013,
  55. Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing vol.35, pp.6, 2015,
  56. Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer vol.13, pp.2, 2016,
  57. Increased cell apoptosis in human lung adenocarcinoma and in vivo tumor growth inhibition by RBM10, a tumor suppressor gene vol.14, pp.4, 2017,
  58. RPiRLS: Quantitative Predictions of RNA Interacting with Any Protein of Known Sequence vol.23, pp.3, 2018,
  59. Mutational landscape of RNA-binding proteins in human cancers vol.15, pp.1, 2018,
  60. CIRBP is a novel oncogene in human bladder cancer inducing expression of HIF-1α vol.9, pp.10, 2018,
  61. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma vol.37, pp.1, 2018,
  62. Prediction of RNA-protein interactions using conjoint triad feature and chaos game representation vol.9, pp.1, 2018,
  63. Cold-inducible RNA binding protein in cancer and inflammation vol.9, pp.2, 2018,